Jonathan Gerber, MD of Levine Cancer Institute, discusses advances in research and treatment trends for AML at the 58th ASH Annual Meeting in San Diego, CA.
CD33, CD47, CAR T-cell and Novel Stem Cell Treatment Trends for 2017
Jonathan Gerber, MD of Levine Cancer Institute, discusses advances in research and treatment trends for AML at the 58th ASH Annual Meeting in San Diego, CA.